# The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure

Study · id `cardio:ct-nct04455178` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04455178](<https://clinicaltrials.gov/study/NCT04455178>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04455178

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04455178. Randomized; no masking; primary purpose treatment. Start 2020-09-23 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04455178, source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)
- Started: 2020-09-23 (actual) (ClinicalTrials.gov record NCT04455178, source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT04455178, source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT04455178, source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04455178, source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04455178-2021-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure
- Acronym: SIRRHF
- Condition: Hypertension
- Intervention (Drug): Spironolactone
- Intervention (Drug): Indapamide
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Indapamide (`cardio:indapamide`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: b75a2c8cd568df10010d9ea530633e716713238824dfa6f0bab5e63c0601f1b0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
